Estimated project duration: until end of 2026 Estimated workload: 20 to 25 hours in total Required Languages: English About the Role We are looking for experienced professionals and subject-matter experts to contribute to an AI training and evaluation project focused on the…
Biotech Investment Analyst — Drug Asset & Company Assessment
Job description
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.
Responsibilities
Create and critique rubrics that analyze commercial drugs and drug-development programs
Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
Apply your assessment across the pilot's set of companies (~5–10)
Requirements
US-based biotech / healthcare investment analyst with a specialist-fund background
Familiarity with biotech/pharma development programs
Able to assess a drug asset and the company behind it end-to-end
5+ years evaluating biotech/pharma companies or assets
Engagement Details
Duration: Approximately 10–20 hours over a 1–2 week pilot
Remote — US-based
Why Participate
Help improve expert AI evaluation of drugs and drug-development programs
Recurring engagement for strong contributors
Who can apply
- Open to
- United States
- Posted
- August 5, 2026 by Mercor
- Last checked
- November 17, 2026: still open on work.mercor.com, where you apply
Opens work.mercor.com in a new tab. If they ask how you found the role, mention RemoWork.